Zevra Therapeutics, Inc.
ZVRA
$8.31
$0.374.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -14.02% | 47.85% | 43.21% | 195.67% | 170.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.02% | 47.85% | 43.21% | 195.67% | 170.26% |
| Cost of Revenue | 241.33% | 651.86% | 430.47% | 555.75% | 878.83% |
| Gross Profit | -35.96% | 10.36% | 19.21% | 182.15% | 154.43% |
| SG&A Expenses | 56.51% | 116.67% | 89.05% | 87.97% | 124.74% |
| Depreciation & Amortization | 707.64% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.53% | 84.40% | 91.01% | 87.79% | 119.79% |
| Operating Income | -75.40% | -98.23% | -113.59% | -59.61% | -99.20% |
| Income Before Tax | -95.75% | -355.42% | -312.64% | -29.18% | -71.79% |
| Income Tax Expenses | -- | -100.00% | -65.23% | 125.00% | 100.00% |
| Earnings from Continuing Operations | -129.13% | -339.38% | -301.09% | -29.72% | -72.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -129.13% | -339.38% | -301.09% | -29.72% | -72.00% |
| EBIT | -75.40% | -98.23% | -113.59% | -59.61% | -99.20% |
| EBITDA | -65.88% | -87.82% | -107.30% | -56.86% | -102.85% |
| EPS Basic | -75.89% | -252.14% | -247.85% | -16.22% | -63.65% |
| Normalized Basic EPS | -51.20% | -256.67% | -253.72% | -119.28% | -431.05% |
| EPS Diluted | -75.89% | -252.14% | -247.85% | -16.22% | -63.65% |
| Normalized Diluted EPS | -51.20% | -256.67% | -253.72% | -119.28% | -431.05% |
| Average Basic Shares Outstanding | 30.43% | 23.70% | 14.38% | 8.12% | 2.79% |
| Average Diluted Shares Outstanding | 30.43% | 23.70% | 14.38% | 8.12% | 2.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
